

HPV vaccination after lesion treatment is likely cost-effective

October 11 2017



(HealthDay)—For HIV-infected men who have sex with men (MSM),

adjuvant quadrivalent human papillomavirus vaccination (qHPV) after treatment of high-grade squamous intraepithelial lesions (HSIL) is likely to be cost-effective, according to a study published online Sept. 12 in *Vaccine*.

Ashish A. Deshmukh, Ph.D., M.P.H., from the University of Florida, Gainesville, and colleagues developed a Markov (state-transition) cohort model to assess the cost-effectiveness of post-HSIL [treatment adjuvant HPV vaccination of HIV-infected MSM \(aged 27 and older\)](#).

Using the willingness-to-pay threshold of \$100,000 per quality-adjusted life-year, the researchers found that treatment plus vaccination was the most cost-effective HSIL management strategy, with an incremental cost-effectiveness ratio of \$71,937 per quality-adjusted life-year. The population-level expected value of perfect information for conducting future clinical research evaluating HSIL management approaches was \$12 million. The expected value of partial perfect information associated with adjuvant qHPV vaccination efficacy, estimated in terms of hazards of decreasing HSIL recurrence, was \$0, suggesting that additional data from a future study evaluating efficacy of adjuvant qHPV vaccination would not change the conclusion that treatment plus vaccination was cost-effective.

"Use of adjuvant qHPV vaccination could be considered as a potential strategy to reduce rising anal cancer burden among these high-risk individuals," conclude the authors.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: HPV vaccination after lesion treatment is likely cost-effective (2017, October 11)
retrieved 9 July 2023 from <https://medicalxpress.com/news/2017-10-hpv-vaccination-lesion-treatment-cost-effective.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.